Attached files
file | filename |
---|---|
EX-31.2 - EX-31.2 - F-star Therapeutics, Inc. | sbph-ex312_6.htm |
EX-31.1 - EX-31.1 - F-star Therapeutics, Inc. | sbph-ex311_8.htm |
10-Q - 10-Q - F-star Therapeutics, Inc. | sbph-10q_20160930.htm |
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Spring Bank Pharmaceuticals, Inc. (the “Company”) on Form 10-Q for the period ending September 30, 2016 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:
|
(1) |
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
|
(2) |
The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company. |
Date: October 28, 2016 |
By: |
/s/ Martin Driscoll |
|
|
Martin Driscoll Chief Executive officer |
|
|
(Principal Executive Officer) |
|
|
|
|
By: |
/s/ Jonathan Freve |
|
|
Jonathan Freve Chief Financial Officer, Treasurer and Secretary |
|
|
(Principal Financial and Accounting Officer) |